Several clinical trials are evaluating the efficacy of combining HDACi with other standard cancer therapies (e.g. aromatase inhibitor, chemotherapy, PARP inhibitors, CDK4/6 inhibitors, anti-HER2 therapy) in breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.